March 25th, 2012
Face to Face with the Living Legends
Tariq Ahmad, MD, MPH
A Fellow gets career advice from his heroes in a new session
March 25th, 2012
Is it Impossible to Break into Clinical Research? Debunking a Common Misperception
Jeremiah Depta, MD
Using the National Cardiovascular Data Registry to identify and pursue good research opportunities
March 25th, 2012
The Pie-ing Game: How Do We Carve up Shrinking Reimbursements?
Sandeep Mangalmurti, MD, JD
The ABCs of RVUs, and how they affect your practice
March 25th, 2012
Eric Peterson to Succeed Bob Harrington as Director of the Duke Clinical Research Institute
Larry Husten, PHD
The Duke Clinical Research Institute has announced that its new director will be Eric Peterson. The DCRI was founded by Robert Califf, who, as the director of the Duke Translational Medicine Institute (DTMI), will be Peterson’s boss. The DCRI’s second director, Robert Harrington, announced earlier this year that he was leaving Duke to become the chairman of the department of medicine […]
March 25th, 2012
Study Supports PCI Without On-Site Surgical Backup
Larry Husten, PHD
Here’s a great example of genuine medical progress: 10% of the first 50 patients who received balloon angioplasty from the procedure’s developer, Andreas Grüntzig, required emergency bypass surgery. By 2002 only 0.15% of PCI patients required emergency surgery, leading many to believe that surgical backup was no longer necessary. Now a large new study provides […]
March 24th, 2012
Whither Conferences? Searching for the South by Southwest Passage
John Ryan, MD
While our conferences shrink, events that put the attendee at the center are growing. What the ACC and AHA learn from the likes of South by Southwest?
March 24th, 2012
Opening with a Bang
Megan Coylewright, MD MPH
Megan Coylewright blogs on the opening session, from Star Wars excess to stem cell disappointment
March 24th, 2012
On the Shoulders of Giants
Tariq Ahmad, MD, MPH
Blogging from ACC.12, Tariq Ahmad pauses to consider the history of innovation in cardiology.
March 24th, 2012
Honoring the Legends
Megan Coylewright, MD MPH
Megan Coylewright reflects on lessons from the five legends honored in ACC’s new lecture series.
March 24th, 2012
Novel Antiplatelet Agent Reduces CV Events But Increases Bleeding
Larry Husten, PHD
Vorapaxar, the novel antiplatelet agent from Merck, appears to effectively reduce cardiovascular death and ischemic events in patients with MI, ischemic stroke, or peripheral vascular disease, but its potential utility is clouded by bleeding complications, including intracranial hemorrhage. Results from the TRA 2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial were presented […]